Myriad’s Next Chapter: New CEO Sam Raha on Growth, AI, and MRD Testing
In his first interview as CEO, Sam Raha discusses Myriad Genetics' pivot to clinical genomics, focusing on oncology, prenatal, and mental health. He highlights plans for AI-powered and MRD tests, aiming for profitable growth while emphasizing patient and provider value.